GeneCure Biotechnologies
GeneCure Biotechnologies is an emerging biotechnology company focused on developing its patented gene transfer technology into effective treatments for various genetic diseases, infectious diseases, and cancers. Their platform technology is based on a primate lentivirus, which has been shown to efficiently deliver therapeutic genes with no harmful side effects. Their lead product is a therapeutic HIV-1 vaccine called HIVAX. The company's strategy involves entering partnerships with pharmaceutical companies to develop gene-based therapeutics, while they focus on early research and pre-clinical studies.
Industries
Nr. of Employees
small (1-50)
GeneCure Biotechnologies
Products
Therapeutic replication-defective lentiviral vaccine (HIV therapeutic candidate)
Replication-defective lentiviral vaccine candidate developed to elicit cellular and antibody immune responses; reported preclinical efficacy in animal models and early-phase clinical safety and immunogenicity data in HIV-positive participants.
Ready-to-use lentiviral reporter vector products
Catalog research products consisting of high-titer lentiviral vectors encoding reporter genes supplied in small aliquots for laboratory use.
Therapeutic replication-defective lentiviral vaccine (HIV therapeutic candidate)
Replication-defective lentiviral vaccine candidate developed to elicit cellular and antibody immune responses; reported preclinical efficacy in animal models and early-phase clinical safety and immunogenicity data in HIV-positive participants.
Ready-to-use lentiviral reporter vector products
Catalog research products consisting of high-titer lentiviral vectors encoding reporter genes supplied in small aliquots for laboratory use.
Services
Supply of purified high-titer lentiviral vectors encoding reporter genes (examples: LacZ, GFP, luciferase) in small aliquots for basic research applications.
Design and production of lentiviral vectors carrying user-specified genes plus characterization of produced vectors.
Large-scale GMP/GLP manufacturing capacity for lentiviral vectors (stated up to 100 L) with onsite cGMP clean-room facilities.
Quality control testing for clinical-grade viral vectors and consultation for QA issues related to IND regulatory submissions.
Supply of purified high-titer lentiviral vectors encoding reporter genes (examples: LacZ, GFP, luciferase) in small aliquots for basic research applications.
Design and production of lentiviral vectors carrying user-specified genes plus characterization of produced vectors.
Large-scale GMP/GLP manufacturing capacity for lentiviral vectors (stated up to 100 L) with onsite cGMP clean-room facilities.
Quality control testing for clinical-grade viral vectors and consultation for QA issues related to IND regulatory submissions.
Expertise Areas
- Lentiviral vector development
- Gene therapy and gene transfer
- Vaccine design using viral vectors
- GMP/GLP viral vector manufacturing
Key Technologies
- Lentiviral vectors (primate lentivirus-based)
- VSV-G pseudotyping
- Packaging cell lines
- Ultracentrifugation concentration
News & Updates
GeneCure's HIVAX Clinical Trial Results
HIVAX has demonstrated safety and strong immune responses in clinical trials, with potential to delay or prevent HIV transmission.
Development of vaccines against infectious diseases
GeneCure is developing vaccines for SARS, Hepatitis B, and Hepatitis C using its platform technology.
GeneCure's Technology Platform
Overview of SimVec gene transfer technology based on SIV, capable of efficient gene delivery into primary human cells.
GeneCure's Approach to HIV Vaccine Development
GeneCure's HIVAX vaccine overcomes limitations of current prime-boost strategies and elicits protective immunity.
Gene Transfer Technology in Clinical Applications
Discussion of gene transfer methods, with a focus on lentiviral vectors and safety profiles.
GeneCure's Platform Technology for Gene Therapy
Details on SimVec technology, its advantages, and potential applications in medicine and research.
GeneCure's HIVAX Clinical Trial Results
HIVAX has demonstrated safety and strong immune responses in clinical trials, with potential to delay or prevent HIV transmission.
Development of vaccines against infectious diseases
GeneCure is developing vaccines for SARS, Hepatitis B, and Hepatitis C using its platform technology.
GeneCure's Technology Platform
Overview of SimVec gene transfer technology based on SIV, capable of efficient gene delivery into primary human cells.
GeneCure's Approach to HIV Vaccine Development
GeneCure's HIVAX vaccine overcomes limitations of current prime-boost strategies and elicits protective immunity.
Gene Transfer Technology in Clinical Applications
Discussion of gene transfer methods, with a focus on lentiviral vectors and safety profiles.
GeneCure's Platform Technology for Gene Therapy
Details on SimVec technology, its advantages, and potential applications in medicine and research.